Skip to content
Commercial Litigation Woods Lonergan LLP

212.684.2500

Copyright Litigation

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

MoneyMakingArticles

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...
Alder Biopharmaceuticals, Inc. - ALDR - Stock Price Today - ZacksZacks Investment Research

all 84 news articles »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

MoneyMakingArticles

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...
Alder Biopharmaceuticals, Inc. - ALDR - Stock Price Today - ZacksZacks Investment Research

all 84 news articles »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Flexion Therapeutics Announces Initial Data from Clinical Trial ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial ...
GlobeNewswire (press release)
BURLINGTON, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced initial findings from its ongoing Phase 3b, open-label study to evaluate the repeat administration of ZILRETTATM (triamcinolone acetonide ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk ...
GlobeNewswire (press release)
BOTHELL, Wash., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that eptinezumab, its lead ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ...
GlobeNewswire (press release)
These risks and uncertainties include, without limitation, risks associated with designing and conducting clinical trials; the fact that preliminary results of ongoing clinical trials or results of past clinical trials may not be predictive of ongoing ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ...
GlobeNewswire (press release)
These risks and uncertainties include, without limitation, risks associated with designing and conducting clinical trials; the fact that preliminary results of ongoing clinical trials or results of past clinical trials may not be predictive of ongoing ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »